Abstracts tagged "Myopathies"

Abstract Number: 1283 • ACR Convergence 2022
Frequency of Checking Creatine Kinase in Patients on Statins with Elevated Transaminase for Early Detection of Statin Induced Myopathy
ANJALI NIDHAAN, Andrei Hastings, david gonzalez, rajshri joshi, nathan gilbert and carolyn o'connor, Cleveland Clinic Akron General, Akron, OH
Background/Purpose: Some of the most commonly reported side effects of statins (widely used lipid lowering agents) are muscle injury (incidence ranging from 0.1-20% based on…
Abstract Number: 1361 • ACR Convergence 2022
Factors Associated with Medication-Free Remission in Juvenile Dermatomyositis
Harneet Ghumman¹, Asra Firdous¹, Megan Quinlan-Waters¹, Amy Cassedy², Angela Merritt¹, Hermine Brunner³, Alexei Grom¹, Daniel Lovell¹ and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cleveland, OH, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis and multi-organ involvement. Treatment with systemic immunosuppression…
Abstract Number: 1637 • ACR Convergence 2022
Association of Dermatomyositis with Cardiovascular Disease: A Case-Control Study in the All of Us Research Program
Jill Shah¹, Keya Shah², Daniel Mazori¹, Avrom Caplan¹, Emily Hejazi¹ and Alisa Femia¹, ¹Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, NY, ²Department of Medicine, NYU Langone Hospital - Long Island, Mineola, NY
Background/Purpose: Previous studies on the association of dermatomyositis (DM) with cardiovascular (CV) disease have used combined idiopathic inflammatory myositis cohorts, included only non-United States (US)…
Abstract Number: 1660 • ACR Convergence 2022
Skeletal Myopathy in Systemic Sclerosis Associates with Higher Disease Burden and Mortality
Julie Paik¹, Caoilfhionn Connolly¹, Fredrick Wigley¹ and Laura Hummers², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Univerisity, Baltimore, MD
Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is poorly understood. The etiology of myopathy in SSc is heterogeneous and can result from an inflammation, disuse,…
Abstract Number: 1864 • ACR Convergence 2022
Hepatitis B Exposure and Infection in Idiopathic Inflammatory Myopathies: Prevalence, Presentation, and Treatment Response
Ana Valle¹, Xianhong Xie² and Shereen Mahmood³, ¹Montefiore Medical Center, New York, NY, ²Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY
Background/Purpose: Hepatitis B (HBV) screening in patients with autoimmune conditions is vital prior to the initiation of immunosuppressive therapy given the risk of HBV reactivation.…
Abstract Number: 1871 • ACR Convergence 2022
Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)
Zi Ying Li¹, Siyi Huang², Kevin Xi³, Deepan Dalal⁴ and Anthony Reginato⁵, ¹Roger Williams Medical Center, Providence, RI, ²UCSF Fresno, Fresno, CA, ³Brown University, Providence, ⁴Brown University School of Medicine, Providence, RI, ⁵Brown University, Providence, RI
Background/Purpose: Cardiovascular disease was encountered in 15% of hospital admission from 2016-2017 for patients with idiopathic inflammatory myopathies (IIM) based on the National Inpatient Sample…
Abstract Number: 1877 • ACR Convergence 2022
Nailfold Videocapillaroscopic Abnormalities Correlate with Disease Activity Measures and Cutaneous Damage in Patients with Idiopathic Inflammatory Myopathies
Diane Zisa¹, Aliza Bloostein¹, Deanna Jannat-Khah, DrPH, MSPH¹, Maurizio Cutolo², Vanessa Smith³ and David Fernandez¹, ¹Hospital for Special Surgery, New York, NY, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy, ³Department of Rheumatology, Ghent University Hospital – Department of Internal Medicine, Ghent University, Belgium – Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Gent, Belgium
Background/Purpose: Nailfold videocapillaroscopy (NVC) is a non-invasive tool used to evaluate the microcirculation of patients with connective tissue diseases (CTDs). A specific combination of NVC…
Abstract Number: 0156 • ACR Convergence 2022
Impact of Polymyositis and Dermatomyositis in Patients Admitted with Congestive Heart Failure: An Insight from the National Database
Brinda Basida¹, Sanket Basida², Jasleen Kaur³, Urja Nagadia², mahmoud mansour², Palak Shah⁴ and Monil Majmundar⁵, ¹DMC/Sinai Grace Hospital, Detroit, MI, ²University of Missouri, Columbia, MO, ³DMC/WSU, Saginaw, MI, ⁴Metropolitan Hospital Center, New York Medical College, New York, NY, ⁵University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Polymyositis (PM) and Dermatomyositis (DM) are systemic autoimmune diseases of inflammatory infiltrates in skeletal muscle resulting in chronic muscle weakness. Systemic involvement of the…
Abstract Number: 1882 • ACR Convergence 2022
Efficacy of Immune-apheresis in Patients with Inflammatory Myopathies: A Case Series
Kastriot Kastrati¹, Hanien Rajab², Anna Rader², Elisabeth Anna Aichner², Thomas Karonitsch², Hans-Peter Kiener², Michael Bonelli³, Daniel Aletaha⁴ and Helga Radner³, ¹Division of Rheumatology, Vienna, Austria, ²Medical University Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Medical University Vienna, Wien, Austria
Background/Purpose: Idiopathic inflammatory myopathies (IIM) comprise a heterogenous group of acquired autoimmune diseases characterised by inflammation of muscle and affection of other organs, including lung…
Abstract Number: 0164 • ACR Convergence 2022
Anti-SSa/SSb and Ro52 Status and Pulmonary Function Tests in Patients with Interstitial Lung Disease and Idiopathic Inflammatory Myopathies
Abdullah Ahmed¹, Sonali Narain², Ivana Ilic¹, Can Hu³, Jaspreet Bhatti⁴ and Galina Marder⁵, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Fort Lee, NJ, ⁴Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, ⁵Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with idiopathic inflammatory myositis (IIM). Anti-SSa/SSb and Ro52 are frequently…
Abstract Number: 1884 • ACR Convergence 2022
Idiopathic Inflammatory Myopathies in Alaska Native/American Indian People in Alaska
Vivek Mehta and Elizabeth Ferucci, Alaska Native Tribal Health Consortium, Anchorage, AK
Background/Purpose: Racial disparities have been in noted in various autoimmune disorders. Indigenous North American populations have higher prevalence and severity of a number of autoimmune…
Abstract Number: 0441 • ACR Convergence 2021
A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis
Pedro Machado¹, Richard Barohn², Michael McDermott³, Thomas Blaetter⁴, Tom Lloyd⁵, Aziz Shaibani⁶, Miriam Freimer⁷, Anthony Amato⁸, Emma Ciafaloni³, Sarah Jones⁹, Tahseen Mozaffar¹⁰, Summer Gibson¹¹, Matthew Wicklund¹², Todd Levine¹³, Claus Sundgreen⁴, Tim Carstensen⁴, Karen Bonefeld⁴, Anders Jørgensen⁴, Karina Phonekeo⁴, Andrew Heim¹⁴, Laura Herbelin¹⁴, Michael Hanna¹⁵ and Mazen Dimachkie¹⁴, ¹Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ²University of Missouri - Columbia, Columbia, MO, ³University of Rochester, Rochester, NY, ⁴Orphazyme A/S, Copenhagen, Denmark, ⁵Johns Hopkins University, Baltimore, MD, ⁶Nerve and Musle Center, Houston, TX, ⁷Ohio State University, Columbus, OH, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Virginia, Charlottesville, VA, ¹⁰University of California Irvine, Irvine, CA, ¹¹University of Utah, Salt Lake City, UT, ¹²University of Colorado, Denver, CO, ¹³Phoenix Neurological Associates, Phoenix, AZ, ¹⁴University of Kansas Medical Center, Kansas City, KS, ¹⁵University College London, London, United Kingdom
Background/Purpose: Inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy occurring in patients over the age of 45 years. Since immune suppression has…
Abstract Number: 0443 • ACR Convergence 2021
Safety and Efficacy of Belimumab in the Treatment of Adult Idiopathic Inflammatory Myositis (Polymyositis and Dermatomyositis)
Priyal Chadha¹, Sonali Narain², Preeya Nandkumar³, Cristine Sison⁴, Elena Schiopu⁵, Todd Levine⁶, James Tsang⁷ and Galina Marder⁸, ¹SUNY Upstate Medical University, Syracuse, NY, ²Northwell Health, Great Neck, NY, ³Division of Rheumatology, Department of Medicine, Northwell, Great Neck, NY, ⁴Biostatistics Unit , Department of Molecular Medicine, Feinstein Institutes for Medical Research at Northwell Health, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵University of Michigan, Ann Arbor, MI, ⁶Phoenix Neurological Associates, Phoenix, AZ, ⁷Center for Research Informatics & Innovation (CRII), Feinstein Institute for Medical Research at Northwell Health, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁸Division of Rheumatology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: Treatment of Idiopathic Inflammatory Myositis (IIM) includes steroids and immunosuppressive agents. Targeting IL6, IL1, TNF for treatment of IIM has not been successful, and…
Abstract Number: 0697 • ACR Convergence 2021
Detection of Autoantibodies Against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort
Angeles Shunashy Galindo-Feria¹, Begum Horuluoglu¹, Jessica Day², Catia Cerqueira³, Edvard Wigren⁴, Susanne Gräslund⁴, Susanna Proudman⁵, Ingrid E Lundberg⁴ and Vidya Limaye⁶, ¹Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ³4Dcell, Montreuil, France, ⁴Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁵University of Adelaide, Medindie, Australia, ⁶Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Autoantibodies targeting a muscle-specific autoantigen, four-and-a-half-LIM-domain 1 (FHL1), have been previously identified in patients with idiopathic inflammatory myopathies (IIM) (1). The aim of this…
Abstract Number: 0701 • ACR Convergence 2021
Use and Yield of Computed Tomography as a Cancer Surveillance Method in Idiopathic Inflammatory Myositis
Christopher Mecoli¹, Brant Chee², XingYao Wang³, Mengkun Chen⁴, William Kelly³, Elizabeth Platz⁴, Livia Casciola-Rosen⁵, Lisa Christopher-Stine³ and Ami Shah⁶, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Applied Physics Laboratory, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins School of Public Health, Baltimore, MD, ⁵Johns Hopkins, Baltimore, MD, ⁶Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: To inform guidance for cancer surveillance in patients with idiopathic inflammatory myositis (IIM), we conducted a retrospective cohort study in a single tertiary referral…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].